The National Agency for Food and Drug Administration and Control (NAFDAC) has given approval for the production of chloroquine for clinical trials in the bid to find effective drug for COVID-19.
NAFDAC Director-General, Mojisola Adeyeye, made this known in a media briefing at the agency’s headquarters. She however emphased that the approval is not for production of the drug for use as it will still undergo the required trials.
“NAFDAC is not approving Chloroquine as a product that has can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials Nobody should use chloroquine as anti-malaria because of the resistance that has been proven to develop in the past after the use of chloroquine in the population”.
President Trump of United States had on Thursday stated that the Food and Drug Administration has approved the production of the dtrug for the treatment of the virus, an information the vagency has since denied on Friday. China who were said to have used the same drug to cure some of its COVID-19 patients has warned that the drug could be dangerous to children.